Potentiating CD16-Activated ADCC in CAR-NK Cell Therapy
NK cells recognize cell-bound antibodies via CD16A (FcγRIIIA) to mediate antibody-dependent cellular cytotoxicity (ADCC). Potentiating therapeutic mAb-mediated CD16 activation of NK cells is an emerging area for cancer immunotherapy.
CAR-NK cells with multi-specific molecules composed of stabilized CD16 and/or other activating receptors (e.g., NKG2D, DNAM-1/CD226, NKp46/NCR1, NKp44/NCR2, and NKp30/NCR3), scFvs for tumor antigens (e.g., CD19, CD22, ROBO1, and PSMA), and cytokine moieties (e.g., IL-15) are being actively studied to augment ADCC. Genetic modifications of CD16 to abolish the sensitivity to ADAM-17 mediated proteolytic cleavage or enhance its affinity for IgG Fc region has shown promising progress. CAR-NK cells expressing CD16A in recombination with the high-affinity Fc receptor, CD64 (FcγRI), show a more stable and enhanced ADCC response, presenting it as a promising advancement in CAR-NK cell immunotherapy.
Sino Biological has developed a panel of quality proteins and antibodies for CD16 and accompanying molecules to support CAR-NK cell therapy research.
